PTK2 and breast cancer: Our studies demonstrate that ECM rigidity is a major determinant of PRL signals to the pro-tumor FAK/SFK/ERK1/2 signaling cascade via activation of focal adhesion signaling, elucidating regulation of the downstream signals of PRL and providing a potential therapeutic target in aggressive luminal breast cancers.